Geneva, Switzerland, September 8, 2015 – Amal Therapeutics, a Geneva based start-up Biotech Company developing and progressing therapeutic vaccines in oncology, announced today that it signed research collaboration agreement with the Oslo University Hospital (OUH)-Radiumhospitalet (Dept of Cellular Therapy). The objective of the collaboration is to validate Amal Therapeutics lead vaccine candidate using human-cells functional […]
Geneva, Switzerland, June 26, 2015 – Amal Therapeutics announced today that part of its recent research findings about a new type of recombinant protein cancer vaccines, will be available on-line on the Cancer Research website on Friday June 26, 2015. View PDF
Geneva, Switzerland, November 26, 2014 – Amal Therapeutics, a Geneva based start-up biotech company developing and progressing therapeutic vaccines in oncology, announced today that it received the CTI Start-up Label from Swiss Commission for Technology and Innovation (CTI). This recognition of a promising development places Amal Therapeutics into the selective group of CTI certified Swiss […]
24 July 2014, Geneva, Switzerland and Archamps, France – Amal Therapeutics, a Swiss biotech start-up company, and TransCure bioServices, a French preclinical contract research organization, have obtained a European Eurostars Programme grant, for a total of 1.07 million Euro. This award winning project, named HuVac, aims to use enhanced humanized immune system mouse models for […]
Geneva/Berlin, 30th June 2014. Amal Therapeutics SA, a Swiss and German‐based company focusing on the development of therapeutic cancer vaccines, announced today the appointment of Dr Johanna Holldack as chairman of the board. Dr Holldack brings over 20 years experience in Biotechnology and Drug Development. View PDF
Geneva/Berlin/Ingelheim/Bonn, 20th February 2014. Amal Therapeutics SA, a Swiss and German-based company focusing on the development of therapeutic cancer vaccines, announced today that it has closed its seed financing round. The funds will be used to consolidate the cell-penetrating peptide based technology platform and progress the first vaccine candidate up to pre-clinical development. The investment […]
Amal Therapeutics received the support from the “Eidgenössische Stiftung zur Förderung Schweizerische Volkswirtschaft durch wissenschaftlische Forschung”.
Amal Therapeutics received a CTI grant for a research project in collaboration with the Laboratory of Tumor Immunology, University of Geneva.